Disclosure statement Supported in part by the National Institutes of Health (NIH) (grants R01 AI 073964, U01 AI 110397, K24 AI 106822, and U 01 AI 160087 [to W.P.] and R01 AI065617 [to T.A.C.]). This work was conducted with support from Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences [NIH award UL1 TR001102]) and financial contributions from Harvard University and its affiliated academic health care centers. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health care centers, or the NIH. Disclosure of potential conflict of interest: W. Phipatanakul receives trial support for asthma-related therapeutics from Genentech, Novartis, GSK, Regeneron, and Sanofi. The rest of the authors declare that they have no relevant conflicts of interest.